Please assess the completion status of the following clinical trial:

Trial Title: Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Admission to the PICU with RSV infection~* Need for positive pressure ventilation (invasive and non-invasive)~* Randomization and drug/placebo initiation within 48 hours of admission to Pediatric Intensive Care Unit~Exclusion Criteria:~* Azithromycin use within 7 days of PICU admission~* Contraindication to azithromycin use including:~  * Patients with electrocardiogram QT interval corrected for heart rate (Qtc) ≥ 450 ms~ * Patients with significant hepatic impairment (direct bilirubin \>1.5 mg/dL)~ * Known hypersensitivity to azithromycin, erythromycin, any macrolide, or ketolide drug~ * Cardiac arrhythmia~* History of pyloric stenosis~* Immunocompromised children (any cause)~* Current use of any medication known to cause QT prolongation

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Placebo controlled (normal saline) daily for 3 days
- Azithromycin (10 mg/kg) (Type: ACTIVE_COMPARATOR): 10 mg/kg IV Azithromycin daily for 3 days
- Azithromycin (20 mg/kg) (Type: ACTIVE_COMPARATOR): 20 mg/kg IV Azithromycin daily for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).